Novartis’ eye drug on par with Eylea but with fewer injections
admin 21st June 2017 Uncategorised 0Novartis’ eye drug brolucizumab has been proven in trials to be non-inferior to Regeneron/Bayer’s Elyea in treating vision loss in patients with neovascular age-related macular degeneration (nAMD), but with fewer injections than its rival.
More: Novartis’ eye drug on par with Eylea but with fewer injections
Source: News